ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said that 27 evaluable patients for the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for indolent lymphoma were enrolled during October, according to a Monday filing with the Hong Kong bourse.
The cancer drug is known to simultaneously bind CD47 and CD20 expressed on malignant B cells, leading to improved therapeutic outcomes, the filing noted.
The company's shares were down over 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。